Antisense Oligonucleotide Composition Targeting OncomiRs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective methods to inhibit OncomiRs, which are microRNAs that contribute to cancer development, limiting the potential for cancer therapy.
Innovation Solution
A composition containing antisense oligonucleotides targeting specific microRNAs such as hsa-miR-133a, hsa-miR-133b, hsa-miR-346, and hsa-miR-361-3p is developed to inhibit the growth of cancer cells by forming complementary strands with these microRNAs, thereby suppressing their oncogenic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then current treatment protocols are maintained, but the ability to inhibit OncomiRs is insufficient
Solution Approach 1:
The patent segments the approach by identifying and targeting specific individual OncomiRs (miR-21, miR-155, miR-17-5p, miR-19, etc.) with dedicated antisense oligonucleotides, rather than using a general cancer treatment approach. This allows precise inhibition of specific oncogenic microRNAs that drive cancer progression.
Solution Approach 2:
The patent introduces antisense oligonucleotides as intermediary molecules that bind to target OncomiRs to form double-stranded complexes, thereby inhibiting the oncogenic activity of these microRNAs. This intermediary approach enables specific inhibition of OncomiR function without directly affecting the cancer cells themselves.
2Ease of operation
If antisense oligonucleotides are introduced to inhibit target miRNA, then miRNA function is inhibited, but the specific microRNA targets must be identified and selected
Solution Approach 1:
The patent performs preliminary identification and classification of OncomiRs through comprehensive expression analysis using miRNA microarrays before selecting target microRNAs for antisense oligonucleotide therapy. This preliminary screening approach identifies which microRNAs are overexpressed in specific cancer types and have oncogenic functions, thereby guiding the selection of appropriate targets.
Solution Approach 2:
The patent changes the parameter of microRNA expression levels by using antisense oligonucleotides to specifically reduce the abundance of target OncomiRs in cancer cells. This parameter change approach allows selective downregulation of pathogenic microRNAs while maintaining normal physiological microRNA functions.
3Quantity of substance
If comprehensive expression analysis is performed to identify OncomiRs, then more target microRNAs are identified, but the complexity of analysis and target selection increases
Solution Approach 1:
The patent segments the comprehensive list of identified OncomiRs into cancer-type-specific groups and functional categories, allowing researchers to focus on relevant targets for specific cancer indications rather than attempting to address all identified microRNAs simultaneously. This segmentation reduces the complexity of target selection while maintaining comprehensive coverage of oncogenic microRNAs.
Solution Approach 2:
The patent employs a comprehensive miRNA microarray analysis that detects all expressed microRNAs (excessive action), but then selectively focuses on and validates only the most promising OncomiR targets (partial action) for therapeutic development. This approach ensures thorough screening while managing the complexity of target selection by prioritizing high-confidence candidates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits cancer cell growth, contributing to cancer treatment and prevention, including the prevention of cancer recurrence.
Implementation Method 1
by introducing an antisense oligonucleotide having a sequence complementary to a target miRNA into cells, a double strand is formed with a target miRNA in each cell
Data Source
AI summary
Provided is a composition that contains an antisense oligonucleotide to a micro RNA and is capable of inhibiting the growth of cancer cells. The present invention, as one aspect, relates to a composition for suppressing the growth of human cancer cells, the composition containing an antisense oligonucleotide to a micro RNA, wherein the micro RNA is selected from the group consisting of hsa-miR-133a, hsa-miR-133b, hsa-miR-346 and hsa-miR-361-3p. The present invention, as another aspect, relates to a composition for suppressing the growth of human head/neck cancer cells, the composition containing an antisense oligonucleotide to a micro RNA, wherein the micro RNA is selected from the group consisting of hsa-miR-92a, hsa-miR-133a, hsa-miR-133b, hsa-miR-139-5p, hsa-miR-197, hsa-miR-328, hsa-miR-346, hsa-miR-361-3p, hsa-miR-605, hsa-miR-766, hsa-miR-1228, hsa-miR-1252, hsa-miR-1260 and hsa-miR-1271.